Vimarsana
Biggest News Aggregation in the World

Silverstein Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Silverstein Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Silverstein Foundation Today - Breaking & Trending Today

CNBC Squawk Box August 9, 2017 - Vimarsana News

CNBC Squawk Box August 9, 2017

Measure. Overnight in asia, you saw similar concerns as markets in both japan and korea came under pressure the nikkei down by 1. 3 , that is a 2 1 2 month low. Hang seng off by a third in europe, you can see similar concerns playing out there the cac is the biggest loser in the major averages declines of over 1. 25 and for stocks in italy and in spain if you want to check out what has been happening with currencies, the yen has been picking up some ground this morning. It is considered a traditional safe haven right now it looks like the dollaryen is at 109. 77, dollar up against the euro. Al...

WCAU On The Money August 20, 2017 - Vimarsana News

WCAU On The Money August 20, 2017

Silverstein had lifechanging news that set him on a new course. Reporter making smart bets on potential new medicine is how this Venture Capitalist built a 20year career. The stakes got a lot more personal. It wasnt until i saw a specialist when i noticed i had a slight tremor in my left leg that he was able to put it all together and say these are all symptoms of parkinsons disease. Diagnosed at age 49, he discovered he has a genetic form of parkinsons disease. There are no drugs approved to cure it or even slow its course. So jonathan and his wife natalie decided to take action. Given the fa...

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease - Vimarsana News

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

BETHESDA, Md., April 24, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...

Gain Therapeutics Announces Positive Results from the - Vimarsana News

Gain Therapeutics Announces Positive Results from the

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer - Vimarsana News

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

BETHESDA, Md., April 08, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...